rs1459304265
Positions:
Variant summary
Our verdict is Pathogenic. Variant got 14 ACMG points: 14P and 0B. PM1PM2PM4PP5_Very_Strong
The NM_000128.4(F11):c.644_649delTCGACA(p.Ile215_Asp216del) variant causes a disruptive inframe deletion change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000041 in 1,461,892 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Likely pathogenic (★★).
Frequency
Genomes: not found (cov: 32)
Exomes 𝑓: 0.0000041 ( 0 hom. )
Consequence
F11
NM_000128.4 disruptive_inframe_deletion
NM_000128.4 disruptive_inframe_deletion
Scores
Not classified
Clinical Significance
Conservation
PhyloP100: 2.85
Genes affected
F11 (HGNC:3529): (coagulation factor XI) This gene encodes coagulation factor XI of the blood coagulation cascade. This protein is present in plasma as a zymogen, which is a unique plasma coagulation enzyme because it exists as a homodimer consisting of two identical polypeptide chains linked by disulfide bonds. During activation of the plasma factor XI, an internal peptide bond is cleaved by factor XIIa (or XII) in each of the two chains, resulting in activated factor XIa, a serine protease composed of two heavy and two light chains held together by disulfide bonds. This activated plasma factor XI triggers the middle phase of the intrisic pathway of blood coagulation by activating factor IX. Defects in this factor lead to Rosenthal syndrome, a blood coagulation abnormality. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 14 ACMG points.
PM1
In a domain Apple 3 (size 83) in uniprot entity FA11_HUMAN there are 20 pathogenic changes around while only 0 benign (100%) in NM_000128.4
PM2
Very rare variant in population databases, with high coverage;
PM4
Nonframeshift variant in NON repetitive region in NM_000128.4.
PP5
Variant 4-186276275-AACATCG-A is Pathogenic according to our data. Variant chr4-186276275-AACATCG-A is described in ClinVar as [Likely_pathogenic]. Clinvar id is 558063.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
F11 | NM_000128.4 | c.644_649delTCGACA | p.Ile215_Asp216del | disruptive_inframe_deletion | 7/15 | ENST00000403665.7 | NP_000119.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
F11 | ENST00000403665.7 | c.644_649delTCGACA | p.Ile215_Asp216del | disruptive_inframe_deletion | 7/15 | 1 | NM_000128.4 | ENSP00000384957.2 | ||
F11 | ENST00000452239.1 | c.89_94delTCGACA | p.Ile30_Asp31del | disruptive_inframe_deletion | 2/6 | 5 | ENSP00000397401.1 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD3 genomes
Cov.:
32
GnomAD4 exome AF: 0.00000410 AC: 6AN: 1461892Hom.: 0 AF XY: 0.00000275 AC XY: 2AN XY: 727246
GnomAD4 exome
AF:
AC:
6
AN:
1461892
Hom.:
AF XY:
AC XY:
2
AN XY:
727246
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome Cov.: 32
GnomAD4 genome
Cov.:
32
Alfa
AF:
Hom.:
ClinVar
Significance: Pathogenic/Likely pathogenic
Submissions summary: Pathogenic:2
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Hereditary factor XI deficiency disease Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Nov 16, 2023 | Variant summary: F11 c.644_649delTCGACA (p.Ile215_Asp216del) results in an in-frame deletion that is predicted to remove two amino acids from the encoded protein. The variant was absent in 251372 control chromosomes (gnomAD v2 Exomes dataset). c.644_649delTCGACA has been reported in the literature in at least one compound heterozygous as well as several heterozygous individuals affected with Hereditary factor XI deficiency disease (e.g., Zadra_2004, Dossenbach-Glaninger_2006, Fard-Esfahani_2007, Bicocchi_2013, Najm_2018). These data indicate that the variant is likely to be associated with disease. At least one publication reports experimental evidence evaluating an impact on protein function, finding that the variant results in <1% FXI coagulant activity and 17% FXI antigen levels relative to wild-type in conditioned media in vitro, which is likely due to impaired folding and secretion (e.g., Zadra_2004). Additionally, co-transfection with the wild-type and variant proteins only partially rescued secreted antigen levels to approximately 63% suggesting a potential dominant-negative impact of the variant (Zadra_2004). The following publications have been ascertained in the context of this evaluation (PMID: 23305485, 16519703, 18005151, 30261521, 15531455). One submitter has reported clinical-significance assessments for this variant to ClinVar after 2014 and has classified the variant as pathogenic/likely pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Counsyl | Apr 26, 2018 | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at